EZH2 and breast cancer: More recently, we demonstrated that USP30-AS1 is significantly upregulated in breast cancer, particularly in triple-negative subtype, where it promotes tumor proliferation through both the hnRNP-F/P21 and EZH2/c-Myc/p21 axes [31].